Similarly, the phase III J-ALEX trial in 207 Japanese ALK-positive NSCLC patients demonstrated the superiority of alectinib in terms of PFS over crizotinib (HR 0.34, 95% CI: 0.17–0.71, p < 0.0001), and delayed risk of CNS progression in patients with BM at baseline (HR 0.16, 95% CI: 0.02–1.28) and those without (HR 0.41, 95% CI: 0.17–1.01). The gene discussed is ALK; the disease is non-small cell lung carcinoma.